Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy – Blood Journals Portfolio
A recent study published by Blood Journals Portfolio (May 2024) available here demonstrates that recombinant ADAMTS13 (rADAMTS13) offers significantly more efficient ADAMTS13 replacement than traditional plasma infusions in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
This finding marks a critical step forward in targeted therapy for patients with severe ADAMTS13 deficiency, a condition that leads to life-threatening microangiopathic hemolytic anemia and thrombocytopenia. Unlike plasma, which delivers ADAMTS13 in variable and limited concentrations, recombinant formulations offer predictable pharmacokinetics, higher bioavailability, and eliminate the risks associated with plasma-derived products, including allergic reactions and pathogen transmission.
These results underscore the potential of rADAMTS13 to become the standard of care in managing cTTP, improving prophylactic and acute-phase treatment outcomes.
Blood Journals Portfolio shared on X:
“Recombinant ADAMTS13 can supply ADAMTS13 more efficiently than plasma to patients with congenital thrombotic thrombocytopenic purpura.”
Title: Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data
Autors: Kazuya Sakai, Atsushi Hamamura, Yoshiko Yoshimura, Miyuki Abe, Yoshiyuki Ogawa, Kazuki Tanaka, Norimichi Hattori, Tazuko Tokugawa, Rie Kanai, Fumiyoshi Ikejiri, Masahiro Takeyama, Teruhisa Taoka, Naoki Fujita, Minoru Kanaya, Katsuyoshi Koh, Hiroshi Shiragami, Hidekazu Azumi, Kenki Saito, Masanori Matsumoto
See more in-depth professional insights at Hemostasis Today, where we bring you the latest advances in thrombosis, hemostasis, and rare bleeding disorders.
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 14, 2025, 12:52JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
-
Aug 14, 2025, 12:33Louise Bannon: The World Thrombosis Day Campaign is Calling on Industry Leaders
-
Aug 14, 2025, 10:58Thomas Reiser: Why October 13 Marks World Thrombosis Day?
-
Aug 14, 2025, 04:03Perioperative Thrombotic Risk Guide for Hematology Fellows
-
Aug 14, 2025, 23:47Health-related Quality of Life in Children with von Willebrand Disease
-
Aug 14, 2025, 17:54Omid Seidizadeh: From Genotype and Phenotype! Variability in Type 2 von Willebrand Disease
-
Aug 14, 2025, 17:36Samin Mohsenian: Thrombotic Paradox in Congenital Fibrinogen Deficiencies
-
Aug 14, 2025, 17:10Emmanuel J Favaloro: DOACs and Mechanical Coagulation Test Systems
-
Aug 14, 2025, 13:09Thrombin Generation Assay to Guide Factor Therapy With Fitusiran
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot